Adelaide Capital Virtual Covid & Healthcare Conference - (Nasdaq ; TSX: IMV) April 23, 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Adelaide Capital
Virtual Covid & Healthcare Conference
(Nasdaq ; TSX: IMV)
April 23, 2020
Forward-looking Statements
• This presentation contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in
the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made.
• Such forward-looking statements include, but are not limited to, statements regarding the Company’s intention to develop a DPX-based vaccine candidate against COVID-19,
the Company’s belief that the DPX-based platform creates the opportunity for accelerated development and rapid, large-scale production of a COVID-19 vaccine, the
Company’s belief in the potential efficacy of its DPX-based vaccine against COVID-19, the Company’s belief in the benefits of the third-party research and studies in related
coronavirus and SARS studies and third-party sequencing data and their applicability to the Company’s DPX platform and a DPX platform related vaccine and the Company’s
anticipated results from its DPX cancer and infectious disease studies. no responsibility to update forward-looking statements in this press release except as required by law.
These forward-looking statements involve known and unknown risks. Such statements should not be regarded as a representation that any of the plans will be achieved.
• Actual results may differ materially from those set forth in this presentation due to risks and uncertainties affecting the Company and its products. The Company assumes no
responsibility to update forward-looking statements in this press release except as required by law. These forward-looking statements involve known and unknown risks and
uncertainties and those risks and uncertainties include, but are not limited to the Company’s ability to develop a DPX-based vaccine candidate against the COVID-19 through
the successful and timely completion of clinical trials and studies, the receipt of all regulatory approvals by the Company to commence and then continue clinical studies, and,
if successful, the commercialization of its proposed vaccine candidate related to COVID-19, the Company’s ability to raise sufficient capital to fund such clinical trials and
studies and the production of any COVID-19 vaccine, the ultimate applicability of any third-party research and studies in related coronavirus and SARS studies and sequencing,
the Company’s ability to enter into agreements with the proposed lead investigators to assist in the clinical development on its vaccine candidate related to COVID-19, the
Company’s ability to collaborate with governmental authorities with respect to such clinical development, the coverage and applicability of the Company’s intellectual property
rights to any vaccine candidate related to COVID-19, the ability of the Company to manufacture any vaccine candidate related to COVID-19 rapidly and at scale and other risks
detailed from time to time in the Company’s ongoing filings and in its annual information form filed with the Canadian regulatory authorities on SEDAR as www.sedar.com and
with the United States Securities and Exchange Commission on EDGAR at www.sec.gov/edgar.
• Investors are cautioned not to rely on these forward-looking statements and are encouraged to read the Company’s continuous disclosure documents which are available on
SEDAR and on EDGAR.
2
© 2020 IMV Inc. All rights reserved.
COVID-19 Pandemic
No return to ‘normality’ until coronavirus vaccine
is available
“Canadians won’t be able to return to life as they
knew it before the novel coronavirus pandemic
until a vaccine is available”, said Prime
Minister Justin Trudeau (2020/04/16)
2020/04/13
3
© 2020 IMV Inc. All rights reserved.
IMV At a Glance
New Class of Immunotherapies & Vaccines
DPX™ delivery platform with a new mechanism of action to program immune cells in-vivo
Peptide epitopes as “information molecules” to direct immune responses against molecularly defined targets
Delivered some of the best-in-class results positioning IMV as one of the leaders in precision immunology
Focused on unmet medical needs for faster clinical path to market
Clinically-demonstrated activity with excellent safety profile across all clinical studies (P1&2, n>330)
Phase 2 in late-stage cancers with high unmet medical needs (e.g. ovarian) with potential for accelerated approval
Applying DPX™ technology to other market opportunities with partners (including COVID-19)
Strong organization
Experienced leadership with successful track-record from clinical to commercialization in cancer and vaccines
Recognized partners (Merck, Wistar, Leidos/NIH, Zoetis….)
4
© 2020 IMV Inc. All rights reserved.
DPX: Immune-Targeted Delivery Platform
Unique “NO-RELEASE” delivery
system forcing an active uptake
and in vivo delivery of active
ingredients into immune cells
and lymph nodes
5
© 2020 IMV Inc. All rights reserved.
Clinical Pipeline
Top line update in 2020
Updated results to be
presented in Q2 2020
Clinical phase 1 to be initiated
during summer 2020
/CPA: oral intermittent low-dose cyclophosphamide (CPA) as an immune modulator
6
© 2020 IMV Inc. All rights reserved.
ts reserved.
Clinical Demonstrations in Cancer
Multiple Phase 1&2 completed and ongoing in 6 cancer indications
Strong sustained T cell
activation against cancer
Activity in hard-to-treat
solid and blood cancers
Phase 1
Phase 2a
(ovarian and lymphoma) Phase 2b
Registration
Long duration of clinical
responses
Favorable safety profile
7
© 2020 IMV Inc. All rights reserved.
Demonstrations in Infectious Diseases
Across a broad range of diseases
Disease Target Results Partners Reference(s)
RSV SHe N=40; well tolerated; robust antigen VIB Langley et al, 2019, JID
B cell epitope specific immune responses at both dose CCfV
levels in all subjects
Anthrax rPA Induced protective immune responses to NIAID Weir et al, npj vaccines, 2019
challenge in both rabbits and NHPs (N=
6-8)
Malaria CSP, RCR RCR complex; murine studies Leidos Healer et al, ASTMH abstract
complex, VLPs downslected DPX as the most potent of 2019
three candidate formulations
Ebola Rabies vector DPX formulation 100% protective in NHP NIAID unpublished
with GP challenge study (N=4)
Influenza rHA/inact Demonstrated cross strain protection in CCfV/ unpublished
virus/VLP mouse challenge studies (inactived virus) Medicago
8
© 2020 IMV Inc. All rights reserved.
DPX-COVID-19
• Differentiated from other vaccine technologies
➢ Hundreds of immunological targets on SARS-Cov-2 but only a few
have capacity to neutralize and prevent infection
➢ DPX COVID-19 is designed to specifically target the neutralizing
epitopes on the spike protein of the virus
➢ Potential to improve on the safety and efficacy of vaccination
against COVID-19
• Based on a clinically demonstrated approach with another respiratory
virus (RSV or the Respiratory Syncytial Virus)
➢ Also supported by a significant clinical data set in the elderly
population and people with other existing conditions such as
cancer and who are believed to be at greatest risk for COVID-19
• Speed and large-scale manufacturing
➢ Fully synthetic like mRNA and DNA technologies
➢ Speed to cGMP production and clinical studies
➢ Potential for very large scale commercial production
Different approaches to develop a vaccine against COVID-19
9
© 2020 IMV Inc. All rights reserved.
DPX-RSV as a Blueprint For DPX-COVID-19
RSV B cell epitope vaccine design Clinical Results (n=40)
High antibody titers generated in 100% of subjects and
can be maintained for more than one year
23 a.a. B cell epitope ( ) Anti RSV SH antibody titers
Lyophilized vaccine Diluent for
content reconstitution
10 to 25 µg peptide + lipid
Mineral oil (ISA51 VG)
nanoparticles
Antibodies bind target protein and are functional
Ab binding to target Ab-dependent phagocytosis
7
*** *
P LA C E B O
6 Placebo *** **
A LO H She
p h a g o c y to s is
5
RSV(A) Alum
IM V S h e
DPX-RSV(A)
4
3
50 µl intramuscular administration
%
2 PBS
1
d ay 0 d ay 84 d ay 421
Langley et al, J Infect Dis 2018
10
© 2020 IMV Inc. All rights reserved.DPX-COVID-19 Vaccine Design
Immunoinformatic epitope mapping analysis
> 1000s epitopes predicted and selected
Functional analysis based on
previous experimental biological
results
Prioritization ~ 23 target neutralizing
epitopes
Ahmad et al Viruses (2020)
11
© 2020 IMV Inc. All rights reserved.DPX-COVID-19 Preclinical Studies
B cell epitope vaccine design Formulation
Lyophilized vaccine Diluent for
content reconstitution
25 µg peptides + Lipid
Mineral oil (ISA51 VG)
Validation and prioritization based on nanoparticles
immunogenicity and neutralization in
preclinical studies
50 µl intramuscular administration
Phase 1 clinical study
12
© 2020 IMV Inc. All rights reserved.DPX-COVID-19 Proposed Phase 1 Trial
52 Subjects Randomized
Objectives
❖ To demonstrate that 1 or 2 doses of DPX-
COVID-19 is well tolerated by healthy Group 1 (Low dose) Group 2 (High dose)
participants Prime + Boost Prime + Boost Single dose
❖ To determine if antibody to the novel antigen DPX-COVID19 DPX-COVID19 DPX-COVID19
can be produced following one or two doses of 2 doses (D0, 56) 2 doses (D0, 56) 1 dose (D0)
8 Subjects 16 Subjects 16 Subjects
DPX-COVID-19
❖ To determine if antibody to the novel antigen Placebo Placebo Placebo
can be induced and can neutralize the virus in D0, 56 D0, 56 D0
4 Subjects 4 Subjects 4 Subjects
neutralization assay in vitro
13
© 2020 IMV Inc. All rights reserved.Key Upcoming Milestones
Milestones Key dates
Updated phase 2 clinical results for Basket trial Q2 2020
Top line phase 2 clinical results update in the ovarian monotherapy trial H2 2020
Top line phase 2 clinical results update in the DLBCL combination trial 2020
Potential initiation of phase 1 clinical trial for DPX-COVID 19 Summer 2020
14
© 2020 IMV Inc. All rights reserved.Stock Information (April 20, 2020)
Analyst Coverage (9)
Ticker: IMV (Nasdaq & TSX)
Market cap: $US 91M / $CAD 129M USA
1. B. Riley FBR
Outstanding shares (as at 03/30/2020) 2. BTIG
Basic : 51.0 M 3. HC Wainwright
Fully diluted : 53.0 M 4. Oppenheimer
5. Raymond James
Recent stock price – Nasdaq $US 1.79 : TSX - $CAD 2.53 6. Wells Fargo
52 Week Trading Range - Nasdaq: $US 1.35 - $US 5.12
Canada
52 Week Trading Range - TSX: $CAD 1.98 - $CAD 6.69
1. Echelon Partners
Average daily volume (US & Canada) ~477 k shares 2. Mackie Research
(as at 04/20/2020, last 30 trading days, includes alternative exchanges in Canada)
3. National Bank of Canada
15
© 2020 IMV Inc. All rights reserved.Nasdaq & TSX: IMV © 2020 IMV Inc. All rights reserved.
You can also read
